Eberconazole Wassermann-SEEFT SA/Laboratories Salvat SA

Current Opinion in Anti-infective Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 416-419

  Muller, F M C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; EBERCONAZOLE; ERGOSTEROL; KETOCONAZOLE;

ANTIFUNGAL ACTIVITY; CLINICAL TRIAL; DRUG SYNTHESIS; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0033853973     PISSN: 14648458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. New topical antifungals
2. New tropical antifungal drugs
3. Wassermann/Salvat eberconazole collaboration
4. Inhibition of two imidazole antimycotics, eberconazole and clotrimazole, by different components of Candida albicans serotype B membrane protoplasts
5. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS-2160) cream 1% and 2%: A phase II dose-finding pilot study
6. Inhibition of two imidazole antimycotics, eberconazole and clotrimazole, by different components of Candida albicans serotype B membrane protoplasts
7. Profile of a new antimycotic eberconazole
8. Salvat looking for licensing partners
9. Laboratorios Salvat SA.
10. Importance of antifungal drug-resistance: Clinical significance and need for novel therapy
11. Current and emerging azole antifungal agents
12. Nuevos antifungicos. Presente y future
13. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole
14. Eberconazole. WAS 2160
15. Tratamiento topico de la candidosis cutanea experimental del cobayo con eberconazol
16. Eberconazole nitrate. Antifungal
17. Actualidades terapeuticas en las infecciones por hongos
18. Recent advances in the treatment of dermatophytosis and the tinea unguium
19. Profile of a new topical antimycotic, eberconazole
20. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
21. The use of systemic antimycotics in dermatotherapy
22. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis
23. A phase II dose finding pilot study: Topical treatment of tinea corporis an tines cruris with eberconazole (WAS 2160) cream
24. Eberconazole a new azole antifungal drug: Comparative in vitro susceptibility of clinical yeast isolates